Winter 2024
Protein Engineering and Services
Monoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles are now hitting markets and pipelines. A range of bispecific antibodies and antibody-drug conjugates – along with CAR-Ts, TCR-RTs and NK cell-based immunoreceptor constructs – were in focus at the PEGS Europe Summit.
Monoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better
target selectivity and safety profiles are now hitting markets and pipelines. A range of bispecific antibodies and antibody-drug conjugates – along with CAR-Ts, TCR-RTs and NK cell-based immunoreceptor constructs – were in focus at the PEGS Europe Summit.
In this Special:
- New proteins on the block
- New antibody formats need costum research
- Interview: Nina Kreymborg, SVP/CSO Partner Team, Curie.bio – a new knowledge-driven VC investor
- Getting to the next stage in ADC development
